---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-08-18T09:27:57.672376'
end_time: '2026-08-18T09:39:57.180730'
duration_seconds: 719.51
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Loeys-Dietz Syndrome 2
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 21
reference_validation:
  total_references: 10
  verified: 10
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 10
  on_topic: 4
  validator_version: 0.2.1
artifact_count: 1
artifact_sources:
  edison_answer_artifacts: 1
artifacts:
- filename: artifact-00.md
  path: Loeys-Dietz_Syndrome_2-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Loeys-Dietz Syndrome 2
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Loeys-Dietz Syndrome 2** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Loeys-Dietz Syndrome 2
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Loeys-Dietz Syndrome 2** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


# Loeys–Dietz Syndrome Type 2 (LDS2): Comprehensive Disease-Characteristics Report

**Scope and evidence convention.** LDS2 means **TGFBR2-related Loeys–Dietz syndrome**, not the entire genetically heterogeneous LDS spectrum. Many natural-history and management publications combine LDS genotypes; therefore, every numerical estimate below is labeled **LDS2-specific** or **pan-LDS**. Evidence types are identified as human clinical, guideline/expert review, in vitro, or animal-model evidence. Literature was prioritized through 2024; one informative 2025 LDS2 case report is included as a post-cutoff development.

| Domain | Compact knowledge-base summary |
|---|---|
| Identity / identifiers | **Disease:** Loeys-Dietz syndrome type 2 (LDS2), the **TGFBR2-related** subtype of Loeys-Dietz syndrome; **MONDO:** `MONDO:0012427`; **Category:** Mendelian connective-tissue/aortopathy disorder; **Gene:** `TGFBR2` / ENSG00000163513; historical subtype nomenclature distinguishes LDS2 from broader LDS spectrum (OpenTargets Search: Loeys-Dietz syndrome 2-TGFBR2, verstraeten2021loeys–dietzsyndrome pages 1-3, takeda2016pathophysiologyandmanagement pages 3-4) |
| Cause / inheritance | **Primary cause:** heterozygous **germline pathogenic variants in TGFBR2**; inheritance is **autosomal dominant** with **variable expressivity** and reported nonpenetrance/de novo cases in broader LDS literature; **share of LDS due to TGFBR2:** **55–60%** (LDS2-specific within broad LDS) (verstraeten2021loeys–dietzsyndrome pages 1-3, meester2017differencesinmanifestations pages 4-5) |
| Hallmark phenotype | Core phenotype combines **aggressive arterial aneurysm/dissection**, **arterial tortuosity**, and craniofacial/skeletal connective-tissue findings such as **hypertelorism**, **bifid/broad uvula or cleft palate**, craniosynostosis, scoliosis, joint laxity/contractures; **aortic root aneurysm ~95%** is a **broad-LDS** figure, not LDS2-only; dissections can occur at **small diameters** and very young ages (broad LDS), including childhood (verstraeten2021loeys–dietzsyndrome pages 1-3, meester2017differencesinmanifestations pages 4-5, takeda2016pathophysiologyandmanagement pages 3-4) |
| Mechanism / pathophysiology | TGFBR2 encodes a **transmembrane serine/threonine kinase** in TGF-β signaling. Disease-causing variants are predominantly **missense variants in the kinase/STK domain**; functional studies show **reduced canonical SMAD2/3 signaling** in vitro, yet diseased aortic tissue shows **paradoxically increased pSMAD2** and activation of **noncanonical MAPK pathways (ERK1/2, p38)**. Key implicated cells/tissues: **vascular smooth muscle cells**, **adventitial fibroblasts**, extracellular matrix and elastin/contractile-unit architecture, with inflammatory infiltrates in models (takeda2016pathophysiologyandmanagement pages 3-4, takeda2018tgfβsignalingrelatedgenes pages 8-10, cousin2017functionalvalidationreveals pages 9-10) |
| Diagnostics | Diagnosis is based on **clinical suspicion plus molecular confirmation of a TGFBR2 variant**; broad LDS clues include craniofacial findings plus diffuse arterial disease. Differential diagnosis includes **Marfan syndrome**, **vascular Ehlers-Danlos syndrome**, and other **heritable thoracic aortic diseases**. Gene-panel, WES, or WGS testing is useful because phenotypic overlap is substantial and VUS interpretation may require functional data (cousin2017functionalvalidationreveals pages 1-2, meester2017differencesinmanifestations pages 4-5, papatheodorou2022geneticsofheritable pages 2-4) |
| Surveillance | **Echocardiography:** at least **annually**; more often if rapid progression. **Cross-sectional imaging (CTA/MRA):** **head-to-pelvis at diagnosis**, repeat at **1 year**, then every **2–3 years** unless abnormalities require closer follow-up. Children may also need **cervical spine flexion-extension radiographs every 3–5 years** when indicated (broad LDS management, applied to LDS2) (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8) |
| Treatment / current care | Standard care is **blood-pressure reduction** and **prophylactic vascular surgery**. **ARBs** such as **losartan** are commonly used; cited target doses: **2.0 mg/kg/day in children** and **≥100 mg/day in adults**; **beta-blockers** may be combined. Activity advice: avoid **contact sports**, **isometric exertion**, and **exercise to exhaustion**. **Prophylactic aortic root surgery**: about **4.0 cm** in adults for **LDS1/LDS2** in expert management guidance; guideline/review thresholds across TGFBR1/TGFBR2 are approximately **4.2–4.5 cm (42–45 mm)**, individualized by sex, body size, family history, and syndromic severity (verstraeten2021loeys–dietzsyndrome pages 8-9, papatheodorou2022geneticsofheritable pages 2-4, verstraeten2021loeys–dietzsyndrome pages 9-11) |
| Prognosis / outcomes | Major morbidity and mortality are **cardiovascular**, especially **aortic and extra-aortic dissections/rupture**; prognosis is improved by early diagnosis, surveillance, and prophylactic surgery, but risk persists after surgery because disease affects the full arterial tree. Pregnancy is high risk in broad LDS management literature: **arterial dissection 11%** and **uterine rupture 2%**, with highest risk in the perinatal/early postpartum period (broad LDS, not LDS2-only) (verstraeten2021loeys–dietzsyndrome pages 11-12, meester2017differencesinmanifestations pages 4-5, verstraeten2021loeys–dietzsyndrome pages 7-8) |
| Epidemiology | **Disease-specific prevalence/incidence for LDS2 are not established** in the gathered evidence. Broad rare-disease context applies. Within diagnosed LDS cohorts, **TGFBR2 accounts for 55–60%** of cases. A cited large broad-LDS cohort contained **441 patients from 228 families**, but this is not a population prevalence estimate (verstraeten2021loeys–dietzsyndrome pages 1-3, papatheodorou2022geneticsofheritable pages 2-4) |
| Other clinically relevant manifestations | Broader LDS care literature reports increased risk of **allergic disease** (asthma, eczema, allergic rhinitis), **food allergy up to 30%**, and **eosinophilic GI disease or inflammatory bowel disease up to 60%**; **cervical spine instability ~50%** is also reported. These figures are **broad-LDS**, not proven LDS2-specific frequencies (verstraeten2021loeys–dietzsyndrome pages 11-12, verstraeten2021loeys–dietzsyndrome pages 7-8) |
| Evidence gaps | Key gaps include: lack of **LDS2-specific prevalence/incidence**, limited **variant-specific penetrance** estimates, sparse **LDS2-specific omics** and human tissue datasets, few controlled data proving superiority of **beta-blocker vs ARB vs combination therapy**, limited pregnancy outcome data stratified by **TGFBR2**, and reliance on **broad-LDS** rather than subtype-specific frequency estimates for many nonvascular manifestations (liu2025anoveltgfbr2 pages 7-8, papatheodorou2022geneticsofheritable pages 2-4, takeda2016pathophysiologyandmanagement pages 3-4, cousin2017functionalvalidationreveals pages 9-10) |


*Table: This table condenses the most clinically useful and ontology-relevant facts for Loeys-Dietz syndrome type 2, clearly distinguishing broad-LDS values from LDS2-specific evidence. It is useful as a quick curation aid for disease identity, management, and evidence gaps.*

## 1. Disease information

### Definition

LDS2 is an autosomal-dominant, pleiotropic connective-tissue and heritable thoracic aortic disease caused by heterozygous germline pathogenic variants in **TGFBR2**, encoding transforming growth factor-β receptor type II. Its defining hazard is a diffuse, often tortuous arteriopathy with aneurysm, dissection, and rupture that can occur in childhood and at smaller vessel diameters than in nonsyndromic aortopathy. Craniofacial, skeletal, cutaneous, ocular, gastrointestinal, and allergic manifestations vary markedly. TGFBR2 historically accounts for approximately **55–60% of molecularly diagnosed LDS**, although this is a case-series proportion rather than population prevalence. (verstraeten2021loeys–dietzsyndrome pages 1-3, meester2017differencesinmanifestations pages 4-5)

### Identifiers and names

- **MONDO:** **MONDO:0012427**.
- **Causal target:** **TGFBR2**, Ensembl **ENSG00000163513**, transforming growth factor beta receptor 2. Open Targets reports five supporting disease–target evidence records and literature links including PMIDs **16027248, 16928994, 24486179, 26888179, 29392890, 32048120, 32086639**. (OpenTargets Search: Loeys-Dietz syndrome 2-TGFBR2)
- **Common names:** Loeys–Dietz syndrome type 2; LDS type 2; LDS2; TGFBR2-related Loeys–Dietz syndrome; TGFBR2-related syndromic thoracic aortic aneurysm and dissection.
- **OMIM:** commonly represented as **Loeys–Dietz syndrome 2, 610168**; **TGFBR2, 190182**. These identifiers should be verified against the live OMIM record before production ingestion because OMIM was not directly queried here.
- **Orphanet:** LDS is generally catalogued at syndrome level rather than consistently by historical numerical subtype; verify the current ORPHA mapping before assigning an LDS2-specific code.
- **ICD-10-CM/ICD-11 and MeSH:** no reliably specific LDS2 code was established from the retrieved evidence. Use the broad LDS/heritable connective-tissue disorder concept plus manifestation codes—e.g., aortic aneurysm/dissection—rather than implying subtype specificity.

This report synthesizes **aggregated disease-level resources, cohorts, reviews, primary experiments, and one case report**; it is not based on an individual EHR. The 2025 report describes one six-month-old infant and must not be generalized as cohort evidence. (liu2025anoveltgfbr2 pages 7-8)

## 2. Etiology, risk, protection, and gene–environment interaction

### Causal factor

The necessary primary cause is a heterozygous **germline TGFBR2 pathogenic/likely pathogenic variant**. TGFBR2 is a transmembrane serine/threonine kinase receptor that complexes with TGFBR1 and normally activates canonical SMAD2/3 and noncanonical MAPK signaling. Most disease-associated substitutions affect conserved residues in the intracellular kinase domain. (takeda2016pathophysiologyandmanagement pages 3-4, cousin2017functionalvalidationreveals pages 9-10)

### Genetic risk factors

- A pathogenic TGFBR2 allele is the dominant risk factor; inheritance is autosomal dominant, with **50% transmission probability per pregnancy**.
- De novo disease is frequent in pan-LDS experience; intrafamilial variability, incomplete penetrance, and nonpenetrance have been reported. (cousin2017functionalvalidationreveals pages 1-2, meester2017differencesinmanifestations pages 4-5)
- Severe systemic features, arterial tortuosity, hypertelorism, wide scars, small body size, female sex in one high-risk TGFBR2 subgroup, rapid aortic growth, and family history of early dissection influence vascular risk and operative timing. In a review of a **441-patient/228-family** cohort, some women with TGFBR2 variants and marked systemic features dissected below 45 mm. (papatheodorou2022geneticsofheritable pages 2-4)
- No reproducible LDS2-specific modifier gene, protective allele, founder mutation, or anticipation phenomenon is established in the retrieved evidence.

### Environmental and physiologic modifiers

Environment does **not cause** LDS2, but hemodynamic load can modify expression. Hypertension, high-intensity or isometric exercise, collision/contact activity, and pregnancy-related volume/hormonal changes plausibly increase wall stress. Smoking and conventional vascular risks should be avoided, although LDS2-specific effect sizes are unavailable. The disorder is neither infectious nor toxin-mediated.

### Protective factors

No factor prevents inheritance after conception. Clinically protective measures are early molecular diagnosis, blood-pressure control, avoidance of extreme exertion, serial whole-arterial-tree imaging, and prophylactic repair before dissection. These reduce complications rather than curing the molecular defect. Evidence for superiority of one antihypertensive regimen in LDS2 remains weak. (verstraeten2021loeys–dietzsyndrome pages 8-9, papatheodorou2022geneticsofheritable pages 2-4)

## 3. Phenotypes

Frequencies are generally **pan-LDS**, because robust TGFBR2-only denominators are scarce.

| Phenotype and type | Characteristics/course | Frequency/effect | Suggested HPO term |
|---|---|---|---|
| Aortic-root dilatation/aneurysm; imaging sign | Congenital susceptibility; may appear in infancy or later; progressive, highly variable | About **95% pan-LDS** in one management synthesis; not LDS2-specific | Aortic root aneurysm **HP:0002616**; dilatation of aortic root **HP:0005170** |
| Arterial aneurysm/dissection/rupture | Any age; progressive arterial-tree disease; events at small diameters, including childhood | Dissection/rupture reported as early as 3 months in pan-LDS literature | Arterial aneurysm **HP:0002727**; aortic dissection **HP:0002647** |
| Arterial tortuosity | Often congenital; generalized, especially head/neck vessels | Common; precise LDS2 rate unavailable | Arterial tortuosity **HP:0005116** |
| Hypertelorism | Congenital craniofacial sign; stable | Characteristic but variably present | Hypertelorism **HP:0000316** |
| Bifid uvula/cleft or high palate | Congenital; feeding/speech/dental impact depends on severity | Characteristic; exact LDS2 rate unavailable | Bifid uvula **HP:0000193**; cleft palate **HP:0000175**; high palate **HP:0000218** |
| Craniosynostosis | Congenital; may require surgery | Variable | Craniosynostosis **HP:0001363** |
| Scoliosis, pectus, arachnodactyly | Childhood-onset or progressive with growth | Variable | Scoliosis **HP:0002650**; pectus excavatum **HP:0000767**; arachnodactyly **HP:0001166** |
| Joint hypermobility or congenital contractures | Hypotonia/laxity can coexist with clubfoot or finger contractures; pain and reduced function possible | Variable | Joint hypermobility **HP:0001382**; joint contracture **HP:0001371** |
| Cervical-spine instability | Often pediatric; potentially neurologically consequential | Approximately **50% pan-LDS** in one management source | Cervical spine instability **HP:0008462** |
| Translucent/velvety skin, easy bruising, abnormal scars | Lifelong connective-tissue signs | Variable | Translucent skin **HP:0000964**; easy bruising **HP:0000978**; abnormal scarring **HP:0001075** |
| Strabismus/myopia | Often childhood; strabismus may require surgery | Variable; ectopia lentis favors Marfan syndrome rather than LDS | Strabismus **HP:0000486**; myopia **HP:0000545** |
| Atopy/food allergy/EGID/IBD | Often childhood; episodic or chronic; can impair nutrition and quality of life | Food allergy up to **30%** and eosinophilic GI disease/IBD up to **60%**, **pan-LDS**, not LDS2-only | Food allergy **HP:0500093**; asthma **HP:0002099**; eczema **HP:0000964**; eosinophilic esophagitis **HP:0410263** |

The syndrome can substantially affect quality of life through serial imaging and surgery, exercise restrictions, chronic pain/instability, feeding or allergic disease, and fear of dissection. However, no validated LDS2-specific EQ-5D, SF-36, or PROMIS norm was found. Cardiovascular disease remains the principal source of morbidity and mortality. (verstraeten2021loeys–dietzsyndrome pages 11-12, meester2017differencesinmanifestations pages 4-5, verstraeten2021loeys–dietzsyndrome pages 7-8)

## 4. Genetic and molecular information

### Gene and variants

- **TGFBR2:** chromosome **3p24.1** (often rendered 3p24.1; one secondary text appears to contain a 3q typo), seven coding exons; HGNC symbol **TGFBR2**. Live HGNC should be consulted for the current numeric HGNC ID.
- Variants are normally **heterozygous germline** variants. Missense substitutions dominate and cluster in the serine/threonine kinase domain; in one analysis, **91/99 HGMD** and **43/44 ClinVar** pathogenic missense entries were kinase-domain variants. (cousin2017functionalvalidationreveals pages 9-10)
- Frameshift, nonsense, splice, and in-frame indel variants can occur. Truncating alleles require careful interpretation: cardiovascular disease has particularly been associated with truncations predicted to escape nonsense-mediated decay, while simple haploinsufficiency may not reproduce classic receptor-LDS biology. (verstraeten2021loeys–dietzsyndrome pages 1-3)
- Illustrative variants include **p.Gly357Trp**, used in knock-in mice; **c.1255G>T, p.Val419Leu**, functionally validated as loss-of-function; and **c.1005_1007delGTA, p.Glu335_Tyr336delinsAsp**, reported de novo in a six-month-old infant. (liu2025anoveltgfbr2 pages 7-8, cousin2017functionalvalidationreveals pages 1-2, takeda2016pathophysiologyandmanagement pages 3-4)

Population frequency should be evaluated variant-by-variant in gnomAD. A causal LDS2 allele is expected to be absent or extremely rare, consistent with a severe dominant rare disorder. No universal carrier frequency is established. Somatic variants are not the disease mechanism.

### Functional interpretation

For p.Val419Leu, modeling predicted altered ATP-binding/inactive kinase conformations; TGFBR2-deficient HCT116-cell rescue assays showed delayed/reduced SMAD2 phosphorylation and reduced TGF-β-responsive transcription. The authors’ abstract states that the variant “**significantly delayed SMAD2 phosphorylation**” and “**significantly decreased TGF-β-induced gene transcription**,” thereby confirming LDS in that patient. This is **in-vitro functional evidence**, not proof of population penetrance. (cousin2017functionalvalidationreveals pages 1-2, cousin2017functionalvalidationreveals pages 9-10)

Variant classifications must follow ACMG/AMP criteria. A VUS alone should not establish LDS2 or drive irreversible family testing; segregation, phenotype, population frequency, computational evidence, RNA studies where relevant, and validated functional assays may permit reclassification.

### Modifiers, epigenetics, and chromosome abnormalities

No validated LDS2 modifier locus, disease-specific methylation signature, histone alteration, recurrent CNV, translocation, inversion, or aneuploidy was identified. Large deletions involving TGFBR2 would require separate interpretation because classic LDS2 is usually sequence-variant mediated.

## 5. Environmental, lifestyle, and infectious information

There is no infectious agent, occupational exposure, pollutant, radiation exposure, diet, alcohol exposure, or toxin known to initiate LDS2. Lifestyle factors modify **mechanical risk**, not genotype. Avoid tobacco, uncontrolled hypertension, stimulant/vasoconstrictor exposure where clinically relevant, heavy lifting, maximal isometric strain, collision sports, and exercise to exhaustion. Moderate aerobic activity is usually individualized to aortic dimensions, valve function, blood pressure, and prior repair. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 9-11)

Pregnancy is a major physiologic gene–environment interaction. Pan-LDS estimates in one management synthesis were **11% arterial dissection**, mostly aortic, and **2% uterine rupture**, with heightened peripartum and early-postpartum vulnerability. These estimates must not be treated as TGFBR2-only risks. (verstraeten2021loeys–dietzsyndrome pages 11-12)

## 6. Mechanism and pathophysiology

### Causal chain

1. **Upstream genetic lesion:** a heterozygous kinase-domain TGFBR2 variant impairs receptor conformation or catalytic signaling.
2. **Cell-autonomous effect:** reduced ligand-induced TGFBR1/TGFBR2 canonical signaling, including deficient or delayed SMAD2/3 phosphorylation and transcription, is measurable in engineered cells.
3. **Developmental/tissue-context response:** receptor dysfunction alters smooth-muscle differentiation, mechanosensing, extracellular-matrix homeostasis, neural-crest-derived craniofacial development, and intercellular feedback.
4. **The TGF-β paradox:** despite receptor loss-of-function in vitro, diseased aortas can show increased TGF-β ligand, pSMAD2, and noncanonical p38/ERK activity. Proposed explanations include compensatory ligand production, impaired negative feedback, signaling from cells retaining a competent receptor complex, and maladaptive paracrine communication between vascular smooth-muscle cells (VSMCs), fibroblasts, and inflammatory cells. (takeda2016pathophysiologyandmanagement pages 3-4, takeda2018tgfβsignalingrelatedgenes pages 8-10)
5. **Downstream tissue failure:** VSMC contractile dysfunction, medial degeneration, matrix disorganization/elastin injury, adventitial fibrosis, and inflammation reduce arterial-wall resilience.
6. **Clinical manifestation:** progressive root and branch-vessel dilatation, tortuosity, aneurysm, dissection, and rupture; disturbed embryonic TGF-β signaling also produces palate, skull, skeletal, and joint phenotypes.

### Pathways, cells, and ontology suggestions

- **Canonical pathway:** TGF-β receptor signaling/SMAD2–SMAD3. Suggested GO: **transforming growth factor beta receptor signaling pathway (GO:0007179)**; **SMAD protein signal transduction (GO:0060395)**.
- **Noncanonical pathway:** TRAF6–TAK1–p38/JNK and ERK MAPK. Suggested GO: **MAPK cascade (GO:0000165)**.
- **Structural biology:** VSMC contraction, ECM organization, elastin/contractile unit, mechanotransduction, fibrosis. Suggested GO: **extracellular matrix organization (GO:0030198)**, **smooth muscle contraction (GO:0006939)**, **response to mechanical stimulus (GO:0009612)**.
- **Cells:** vascular smooth-muscle cell (**CL:0000359**), fibroblast (**CL:0000057**), endothelial cell (**CL:0000115**), neural crest cell (**CL:0000333**), and leukocyte/CD45-positive inflammatory cells (**CL:0000738**, broad leukocyte concept).

Tgfbr2^G357W/+ mice had increased aortic pSMAD2, thickened media/adventitia, increased **Tgfb1**, and abundant **CD45+** inflammatory infiltrates. By contrast, postnatal smooth-muscle biallelic Tgfbr2 deletion caused thoracic aneurysm and adventitial fibrosis with increased p38/ERK but not increased pSMAD2, showing that model design and residual signaling competence materially affect the phenotype. (takeda2016pathophysiologyandmanagement pages 3-4, takeda2018tgfβsignalingrelatedgenes pages 8-10)

### Molecular profiling and advanced technologies

No mature LDS2-specific clinical transcriptomic, proteomic, metabolomic, lipidomic, methylomic, spatial-transcriptomic, or multi-omic biomarker is validated. Single-cell/iPSC work in **TGFBR1-related LDS**, not LDS2, has shown lineage-specific contractile and ECM defects and rescue with activin A plus rapamycin; it is mechanistically informative but should not be directly assigned to TGFBR2 disease. LDS2-specific single-cell and spatial studies remain a priority.

## 7. Anatomical structures affected

- **Primary organ/system:** cardiovascular system—particularly the **aortic root**, ascending aorta, arch, descending thoracic and abdominal aorta, and medium/large branch arteries. Cerebral, carotid, vertebral, basilar, ophthalmic, pulmonary, coronary, mesenteric, renal, iliac, and peripheral vessels may be involved.
- **Secondary systems:** craniofacial skeleton/palate, cervical spine, axial and appendicular skeleton, joints, skin, eyes, gastrointestinal tract, lungs, and immune/allergic compartments.
- **Tissue:** arterial media and adventitia; connective tissue, smooth muscle, elastic lamellae, ECM, fibroblast-rich adventitia.
- **Subcellular compartments:** plasma-membrane receptor complex, cytoplasmic SMAD/MAPK signaling machinery, nucleus for transcriptional responses, and extracellular matrix.
- **Suggested UBERON:** aortic root **UBERON:0001519**, aorta **UBERON:0000947**, arterial wall **UBERON:0001981**, palate **UBERON:0001716**, cervical vertebral column **UBERON:0006072**, skin **UBERON:0002097**. Verify ontology releases before ingestion.
- Disease is generally systemic and not lateralized; scoliosis, clubfoot, strabismus, and individual aneurysms may be asymmetric.

## 8. Temporal development

LDS2 is a **congenital genetic disorder with lifelong risk**, although clinical recognition ranges from prenatal/neonatal to adulthood. Craniofacial and skeletal signs may be evident at birth; aortic disease can occur during infancy. Pan-LDS dissection or rupture has been reported as early as three months, and the 2025 LDS2 case demonstrated aortic sinus enlargement at six months. (liu2025anoveltgfbr2 pages 7-8, meester2017differencesinmanifestations pages 4-5)

The course is chronic and variably progressive rather than relapsing-remitting. There is no true remission: successful root replacement removes one high-risk segment but does not eliminate distal arterial disease. Critical periods include rapid childhood growth, rapid documented aortic enlargement, pregnancy, delivery/early postpartum, and the period surrounding major surgery. Early diagnosis creates the principal intervention window.

## 9. Inheritance and population

- **Inheritance:** autosomal dominant; offspring risk **50%**.
- **Penetrance:** substantial but not demonstrably complete; may be age-dependent. Nonpenetrance and marked variable expressivity are documented. (cousin2017functionalvalidationreveals pages 1-2, meester2017differencesinmanifestations pages 4-5)
- **De novo/germline mosaicism:** de novo variants are well recognized. Parental germline mosaicism is biologically possible and should be discussed after an apparently de novo result, but no LDS2-specific recurrence percentage is available.
- **Anticipation:** not established.
- **Founder effects/consanguinity:** no established founder allele; consanguinity is not a typical factor in dominant LDS2.
- **Prevalence/incidence:** unknown for LDS2. The 55–60% figure refers to the fraction of diagnosed LDS attributed to TGFBR2, not population prevalence. (verstraeten2021loeys–dietzsyndrome pages 1-3, meester2017differencesinmanifestations pages 4-5)
- **Sex/ethnicity/geography:** both sexes and diverse ancestries are affected. No robust sex ratio, ethnic enrichment, or endemic region is established. Ascertainment and access to cardiovascular genetics likely drive apparent geographic differences.

## 10. Diagnostics

### Clinical evaluation and imaging

Diagnosis begins with personal/family history and examination for early thoracic aortic disease, generalized arterial tortuosity, hypertelorism, bifid uvula/cleft palate, craniosynostosis, skeletal/joint signs, translucent skin, and allergic/GI disease. There are no universally accepted purely clinical LDS criteria; molecular confirmation is central. (meester2017differencesinmanifestations pages 4-5)

Recommended baseline studies include:

- Transthoracic echocardiography with aortic-root Z-score/diameter, ascending aorta, valves, and ventricular function.
- CTA or MRA from **head to pelvis** to identify tortuosity, aneurysms, and dissections outside the echocardiographic field.
- ECG and additional cardiac testing as indicated; these are not diagnostic biomarkers.
- Cervical-spine radiographs, including flexion/extension views when appropriate, before procedures involving neck manipulation.
- Orthopedic, ophthalmic, dental/craniofacial, allergy/immunology, and GI evaluation guided by manifestations.

No blood enzyme assay, circulating protein, metabolite, biopsy, liquid biopsy, or omics signature can confirm LDS2. Histology may show medial degeneration, elastic-fiber fragmentation, fibrosis, and altered TGF-β markers but is neither required nor specific.

### Genetic testing

1. Use a **heritable thoracic aortic disease multigene panel** including at minimum TGFBR2, TGFBR1, SMAD2, SMAD3, TGFB2, TGFB3, FBN1, SKI, COL3A1, ACTA2, MYH11, MYLK, and LOX; contemporary panels may include additional validated HTAD genes.
2. Sequence analysis plus deletion/duplication calling is preferred. Single-gene TGFBR2 testing is reasonable when phenotype or a known familial variant is compelling.
3. WES/WGS is useful after a negative panel, in atypical disease, or where structural/noncoding variation is suspected; genome sequencing is not yet guaranteed to resolve all cases.
4. CMA/karyotype/FISH, mitochondrial DNA, and repeat-expansion testing are **not routine** for classic LDS2 unless a broader differential indicates them.
5. Test the familial variant in first-degree relatives. Prenatal diagnosis and PGT-M are technically possible once the pathogenic familial allele is known.

### Differential diagnosis

- **Marfan syndrome/FBN1:** ectopia lentis and pronounced dolichostenomelia favor Marfan; bifid uvula, hypertelorism, craniosynostosis, and diffuse tortuous arteriopathy favor LDS. (liu2025anoveltgfbr2 pages 5-7)
- **Vascular Ehlers–Danlos/COL3A1:** marked tissue/organ fragility and characteristic vEDS phenotype; surgical behavior differs.
- **Other LDS genotypes:** TGFBR1, SMAD2/3, TGFB2/3, IPO8 and related TGF-β signalopathies.
- **Shprintzen–Goldberg/SKI**, arterial tortuosity syndrome/SLC2A10, congenital contractural arachnodactyly/FBN2, and nonsyndromic HTAD genes.

## 11. Outcome and prognosis

Aortic and arterial dissection/rupture are the principal causes of premature death. Cerebral hemorrhage has caused death in young children in pan-LDS reports. Events may occur at aortic diameters as small as **3.7 cm in adults**, and prophylactic root surgery does not remove distal-vessel risk. (meester2017differencesinmanifestations pages 4-5, verstraeten2021loeys–dietzsyndrome pages 7-8)

The earliest descriptions overrepresented severe disease. The later 441-patient cohort suggested a more favorable overall profile than historical series, highlighting ascertainment bias and broad expressivity. No reliable LDS2-specific 5-year survival, 10-year survival, life expectancy, annual mortality, disability weight, or validated prognostic calculator was found. (papatheodorou2022geneticsofheritable pages 2-4)

Adverse prognostic factors include prior dissection, rapid aortic growth, strong family history, marked systemic phenotype, hypertelorism, arterial tortuosity, wide scars, small body size in some women, uncontrolled blood pressure, and pregnancy. Favorable outcomes depend on early diagnosis, expert surveillance, timely valve-sparing or composite root surgery, and lifelong distal-vessel monitoring.

## 12. Treatment and real-world implementation

### Medical therapy

There is no approved genotype-correcting or disease-eradicating drug. Current practice uses:

- **β-blockers** to reduce heart rate, blood pressure, and aortic impulse.
- **Angiotensin-II receptor blockers**, especially **losartan**, for antihypertensive and potential TGF-β/RAS-modulating effects; expert targets cited are **2.0 mg/kg/day in children** and at least **100 mg/day in adults**, as tolerated.
- Combination β-blocker/ARB therapy may be considered when blood pressure and progression warrant it.

Evidence is extrapolated from Marfan trials, LDS animal models, and expert experience; controlled LDS2 efficacy data remain absent. An authoritative review explicitly noted the lack of published evidence proving benefit in TGFBR1/TGFBR2 carriers. (verstraeten2021loeys–dietzsyndrome pages 8-9, papatheodorou2022geneticsofheritable pages 2-4, verstraeten2021loeys–dietzsyndrome pages 9-11)

Suggested NCIt concepts: **Beta-Adrenergic Blocker**; **Angiotensin II Receptor Antagonist**; **Losartan**; **Antihypertensive Therapy**. Suggested ChEBI: losartan **CHEBI:6541**; verify release-specific identifiers.

### Surgery/intervention

Elective aortic-root replacement—often valve-sparing where anatomy and expertise permit—is the only established way to prevent root dissection. Thresholds are individualized:

- Expert LDS1/2 practice: consider surgery at approximately **4.0 cm** in adults.
- Prior AHA/ACC guidance summarized in a 2022 review: **≥42 mm**.
- ESC guidance summarized there: **≥45 mm** for TGFBR1/TGFBR2.

Lower thresholds may be justified by rapid growth, family history, marked syndromic features, pregnancy plans, small body size, or prior dissection. Root and ascending-aortic replacement may be considered together. Other aneurysms are generally considered for intervention when approximately **2–3 times expected diameter**, but anatomy-specific expert judgment is essential. (verstraeten2021loeys–dietzsyndrome pages 8-9, papatheodorou2022geneticsofheritable pages 2-4, verstraeten2021loeys–dietzsyndrome pages 9-11)

Suggested NCIt: **Aortic Root Replacement**, **Valve-Sparing Aortic Root Replacement**, **Aneurysm Repair**, **Vascular Surgery**.

### Supportive care

Physical therapy should preserve conditioning while avoiding joint injury and extreme loading. Orthopedic care addresses scoliosis, clubfoot, instability, low bone density, and pain. Cleft-palate/craniosynostosis care, ophthalmology, dental care, nutrition, allergy/EGID/IBD therapy, and psychosocial support are phenotype-directed. Cervical instability must be communicated to anesthesia and surgical teams. (verstraeten2021loeys–dietzsyndrome pages 9-11, verstraeten2021loeys–dietzsyndrome pages 7-8)

### Advanced and experimental therapy

No gene replacement, CRISPR, ASO, siRNA, mRNA, cell therapy, or approved TGF-β-targeted therapy is available. Direct systemic TGF-β inhibition is biologically complicated because signaling may be protective early and harmful later. Preclinical models support RAS modulation, but translation remains incomplete.

ClinicalTrials.gov searches found primarily observational or supportive studies rather than LDS2-specific drug trials: **NCT05472519** (immunopathology; completed; n=60), **NCT02504853** (food allergy/natural history; recruiting; n=1,800), **NCT05980104** (single-session pain “Empowered Relief”; completed; n=92), **NCT02213484** (microRNAs in hereditary aortopathy; completed; n=20), **NCT01322165** (GenTAC registry; completed; n=3,706), and **NCT03440697** (aortopathy/aortic-valve pathogenesis; active, not recruiting; n=3,000). These enroll LDS or related disorders and do not establish an LDS2-specific response rate.

## 13. Prevention

- **Primary prevention:** the spontaneous/de novo molecular event cannot presently be prevented. Reproductive options include genetic counseling, PGT-M, chorionic-villus sampling, or amniocentesis after identification of the familial variant.
- **Secondary prevention:** molecular cascade testing, baseline echocardiography, and head-to-pelvis vascular imaging identify presymptomatic relatives.
- **Tertiary prevention:** strict blood-pressure management, annual or more frequent echocardiography, serial CTA/MRA, activity modification, and prophylactic surgery prevent dissection and disability.

Expert surveillance recommends echocardiography **at least annually**, more often with rapid progression; head-to-pelvis MRA/CTA at diagnosis, at **one year**, then every **2–3 years** if stable. Pediatric cervical flexion-extension radiographs may be repeated every **3–5 years** when indicated. (verstraeten2021loeys–dietzsyndrome pages 8-9, verstraeten2021loeys–dietzsyndrome pages 7-8)

Before pregnancy, obtain comprehensive brain-to-abdomen vascular imaging and multidisciplinary counseling. During pregnancy, perform echocardiography at least once per trimester and continue postpartum monitoring; management should occur at a tertiary cardio-obstetric center. (verstraeten2021loeys–dietzsyndrome pages 11-12)

There is no LDS-specific vaccine or infectious prophylaxis. Routine immunization applies.

## 14. Other species and natural disease

No well-established naturally occurring veterinary equivalent of human TGFBR2-related LDS2 was identified in the retrieved literature. Accordingly, no breed-specific VBO term, veterinary prevalence, zoonotic transmission, or cross-species infectious risk applies. TGFBR2 pathway function is evolutionarily conserved across vertebrates, enabling experimental mouse and zebrafish work, but induced genetic models should not be mislabeled as natural animal disease.

Suggested taxa for experimental annotation: **Homo sapiens, NCBI Taxon 9606**; **Mus musculus, 10090**; **Danio rerio, 7955**. Ortholog identifiers should be taken from current NCBI Gene/Alliance records before database ingestion.

## 15. Model organisms and experimental systems

### Knock-in mouse

**Tgfbr2^G357W/+ mice** model a human LDS-associated receptor substitution. They reproduce vascular, craniofacial, and skeletal manifestations and show progressive aortopathy, increased aortic pSMAD2/Tgfb1, wall thickening, and CD45-positive inflammation. This model supports the signaling paradox and permits preventive-drug testing. (takeda2016pathophysiologyandmanagement pages 3-4, takeda2018tgfβsignalingrelatedgenes pages 8-10)

### Conditional knockout models

Postnatal VSMC-specific biallelic deletion—**Myh11-CreERT2;Tgfbr2^fl/fl**—produces thoracic aneurysm, marked adventitial fibrosis, and increased ERK1/2/p38 activation without increased pSMAD2. Cranial-neural-crest Tgfbr2 deletion causes palate and calvarial defects. These models identify cell- and developmental-stage-specific receptor requirements. (takeda2016pathophysiologyandmanagement pages 3-4, liu2025anoveltgfbr2 pages 8-9)

### Cellular and computational models

TGFBR2-deficient **HCT116** cells reconstituted with p.Val419Leu, luciferase reporters, Western blotting, homology modeling, and molecular-dynamics simulations demonstrated reduced canonical signaling and altered kinase conformational dynamics. This combination is useful for VUS adjudication but does not reproduce arterial multicellularity, hemodynamics, or lifelong heterozygosity. (cousin2017functionalvalidationreveals pages 1-2, cousin2017functionalvalidationreveals pages 9-10)

### Limitations

- Homozygous conditional loss is mechanistically different from the human heterozygous missense state.
- Mouse vessel geometry, lifespan, and hemodynamics differ from humans.
- Craniofacial and immune phenotypes vary by genetic background.
- Single-cell and iPSC rescue findings presently available for TGFBR1-LDS cannot automatically be generalized to LDS2.
- No model fully captures variant-specific penetrance, pregnancy risk, distal arterial heterogeneity, or human quality-of-life burden.

## Recent developments and expert assessment, 2023–2024

The 2023–2024 literature increasingly treats LDS2 within **genotype-driven HTAD management**, emphasizing molecular testing, complete arterial-tree imaging, body-size/sex/family-history-adjusted operative thresholds, and the dual role of TGF-β signaling rather than a simplistic “excess signaling” model. Reviews published in 2024 stress that hereditary aneurysms occur younger, without conventional risk factors, and can dissect at smaller diameters; early diagnosis, molecular testing, surveillance, blood-pressure reduction, and prophylactic surgery remain the practical standard. LDS2-specific randomized therapy, biomarker, single-cell, and population epidemiology studies were still lacking through 2024.

A post-cutoff January 2025 case report expands the variant spectrum with de novo **p.Glu335_Tyr336delinsAsp** in a six-month-old infant and reports reduced SMAD2 phosphorylation/transcription in vitro. Its abstract-level conclusion is consistent with prior work, but its designation of LDS2 as the “more aggressive subtype” and its recommended 4.0-cm threshold reflect secondary interpretation and should not supersede individualized guideline care. (liu2025anoveltgfbr2 pages 7-8)

## Curatorial conclusions and evidence gaps

1. **High-confidence entity:** MONDO:0012427 is an autosomal-dominant TGFBR2 disorder with diffuse arteriopathy and multisystem connective-tissue manifestations. (OpenTargets Search: Loeys-Dietz syndrome 2-TGFBR2)
2. **High-confidence mechanism:** most pathogenic missense variants impair receptor kinase/canonical signaling cell-autonomously; compensatory multicellular signaling creates paradoxical lesional SMAD/MAPK activation. (takeda2016pathophysiologyandmanagement pages 3-4, cousin2017functionalvalidationreveals pages 9-10)
3. **High-confidence application:** genetic diagnosis, cascade testing, whole-arterial-tree surveillance, antihypertensive therapy, activity modification, and early surgery are real-world standards. (verstraeten2021loeys–dietzsyndrome pages 8-9, papatheodorou2022geneticsofheritable pages 2-4)
4. **Moderate/low-confidence quantitative phenotyping:** many frequency values—95% root aneurysm, 50% cervical instability, 30% food allergy, 60% GI inflammatory disease, and pregnancy complication percentages—are pan-LDS and must not be stored as LDS2-specific penetrance. (verstraeten2021loeys–dietzsyndrome pages 1-3, verstraeten2021loeys–dietzsyndrome pages 11-12, verstraeten2021loeys–dietzsyndrome pages 7-8)
5. **Major unmet needs:** LDS2 population prevalence/incidence, prospective variant-specific penetrance, validated circulating/omics biomarkers, controlled ARB/β-blocker trials, genotype-stratified pregnancy outcomes, longitudinal quality-of-life data, and TGFBR2-specific single-cell/spatial maps.

### Key source URLs and publication dates

- Loeys et al., *Nature Genetics*, March 2005, discovery paper: https://doi.org/10.1038/ng1511.
- Gallo et al., *Journal of Clinical Investigation*, January 2014: https://doi.org/10.1172/JCI69666. (gallo2014angiotensinii–dependenttgfβ pages 13-13)
- Cousin et al., *Cold Spring Harbor Molecular Case Studies*, July 2017: https://doi.org/10.1101/mcs.a001727. (cousin2017functionalvalidationreveals pages 1-2)
- Meester et al., *Annals of Cardiothoracic Surgery*, November 2017: https://doi.org/10.21037/acs.2017.11.03. (meester2017differencesinmanifestations pages 4-5)
- Takeda et al., *International Journal of Molecular Sciences*, July 2018: https://doi.org/10.3390/ijms19072125. (takeda2018tgfβsignalingrelatedgenes pages 8-10)
- Verstraeten, Dietz & Loeys, management chapter, October 2021: https://doi.org/10.1002/9781119432692.ch36. (verstraeten2021loeys–dietzsyndrome pages 8-9)
- Papatheodorou et al., *Cardiogenetics*, February 2022: https://doi.org/10.3390/cardiogenetics12010006. (papatheodorou2022geneticsofheritable pages 2-4)
- Liu et al., *Heliyon*, January 2025: https://doi.org/10.1016/j.heliyon.2025.e42116. (liu2025anoveltgfbr2 pages 7-8)

References

1. (OpenTargets Search: Loeys-Dietz syndrome 2-TGFBR2): Open Targets Query (Loeys-Dietz syndrome 2-TGFBR2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (verstraeten2021loeys–dietzsyndrome pages 1-3): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

3. (takeda2016pathophysiologyandmanagement pages 3-4): Norifumi Takeda, Hiroki Yagi, Hironori Hara, Takayuki Fujiwara, Daishi Fujita, Kan Nawata, Ryo Inuzuka, Yuki Taniguchi, Mutsuo Harada, Haruhiro Toko, Hiroshi Akazawa, and Issei Komuro. Pathophysiology and management of cardiovascular manifestations in marfan and loeys-dietz syndromes. International heart journal, 57 3:271-7, May 2016. URL: https://doi.org/10.1536/ihj.16-094, doi:10.1536/ihj.16-094. This article has 85 citations and is from a peer-reviewed journal.

4. (meester2017differencesinmanifestations pages 4-5): Josephina A. N. Meester, Aline Verstraeten, Dorien Schepers, Maaike Alaerts, Lut Van Laer, and Bart L. Loeys. Differences in manifestations of marfan syndrome, ehlers-danlos syndrome, and loeys-dietz syndrome. Annals of Cardiothoracic Surgery, 6:582-594, Nov 2017. URL: https://doi.org/10.21037/acs.2017.11.03, doi:10.21037/acs.2017.11.03. This article has 409 citations.

5. (takeda2018tgfβsignalingrelatedgenes pages 8-10): Norifumi Takeda, Hironori Hara, Takayuki Fujiwara, Tsubasa Kanaya, Sonoko Maemura, and Issei Komuro. Tgf-β signaling-related genes and thoracic aortic aneurysms and dissections. International Journal of Molecular Sciences, 19:2125, Jul 2018. URL: https://doi.org/10.3390/ijms19072125, doi:10.3390/ijms19072125. This article has 181 citations.

6. (cousin2017functionalvalidationreveals pages 9-10): Margot A. Cousin, Michael T. Zimmermann, Angela J. Mathison, Patrick R. Blackburn, Nicole J. Boczek, Gavin R. Oliver, Gwen A. Lomberk, Raul A. Urrutia, David R. Deyle, and Eric W. Klee. Functional validation reveals the novel missense v419l variant in tgfbr2 associated with loeys–dietz syndrome (lds) impairs canonical tgf-β signaling. Cold Spring Harbor Molecular Case Studies, 3:a001727, Jul 2017. URL: https://doi.org/10.1101/mcs.a001727, doi:10.1101/mcs.a001727. This article has 10 citations and is from a peer-reviewed journal.

7. (cousin2017functionalvalidationreveals pages 1-2): Margot A. Cousin, Michael T. Zimmermann, Angela J. Mathison, Patrick R. Blackburn, Nicole J. Boczek, Gavin R. Oliver, Gwen A. Lomberk, Raul A. Urrutia, David R. Deyle, and Eric W. Klee. Functional validation reveals the novel missense v419l variant in tgfbr2 associated with loeys–dietz syndrome (lds) impairs canonical tgf-β signaling. Cold Spring Harbor Molecular Case Studies, 3:a001727, Jul 2017. URL: https://doi.org/10.1101/mcs.a001727, doi:10.1101/mcs.a001727. This article has 10 citations and is from a peer-reviewed journal.

8. (papatheodorou2022geneticsofheritable pages 2-4): Efstathios Papatheodorou, Dimitrios Degiannis, and Aris Anastasakis. Genetics of heritable thoracic aortic disease. Cardiogenetics, 12:63-79, Feb 2022. URL: https://doi.org/10.3390/cardiogenetics12010006, doi:10.3390/cardiogenetics12010006. This article has 14 citations.

9. (verstraeten2021loeys–dietzsyndrome pages 8-9): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

10. (verstraeten2021loeys–dietzsyndrome pages 7-8): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

11. (verstraeten2021loeys–dietzsyndrome pages 9-11): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

12. (verstraeten2021loeys–dietzsyndrome pages 11-12): Aline Verstraeten, Harry C. Dietz, and Bart L. Loeys. Loeys–dietz syndrome. Cassidy and Allanson's Management of Genetic Syndromes, pages 563-576, Oct 2021. URL: https://doi.org/10.1002/9781119432692.ch36, doi:10.1002/9781119432692.ch36. This article has 4 citations.

13. (liu2025anoveltgfbr2 pages 7-8): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations.

14. (liu2025anoveltgfbr2 pages 5-7): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations.

15. (liu2025anoveltgfbr2 pages 8-9): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations.

16. (gallo2014angiotensinii–dependenttgfβ pages 13-13): Elena M. Gallo, David C. Loch, Jennifer P. Habashi, Juan F. Calderon, Yichun Chen, Djahida Bedja, Christel van Erp, Elizabeth E. Gerber, Sarah J. Parker, Kimberly Sauls, Daniel P. Judge, Sara K. Cooke, Mark E. Lindsay, Rosanne Rouf, Loretha Myers, Colette M. ap Rhys, Kathleen C. Kent, Russell A. Norris, David L. Huso, and Harry C. Dietz. Angiotensin ii–dependent tgf-β signaling contributes to loeys-dietz syndrome vascular pathogenesis. Journal of Clinical Investigation, 124(1):448-460, Dec 2014. URL: https://doi.org/10.1172/jci69666, doi:10.1172/jci69666. This article has 325 citations and is from a highest quality peer-reviewed journal.

## Artifacts

- [Edison artifact artifact-00](Loeys-Dietz_Syndrome_2-deep-research-falcon_artifacts/artifact-00.md)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 10 |
| Resolved | 10 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 10 |
| On topic | 4 |
| Off topic | 0 |

All extracted references resolved successfully.